Free Trial
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$2.17
-2.3%		$4.21
$2.05
▼
$179.19
$1.28M-0.0744,881 shs45,256 shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.40
-6.1%		$0.47
$0.15
▼
$0.97
$1.32M-0.236,551 shs2,097 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.19
$0.17
$0.00
▼
$6.53
$340K0.51,216 shs403 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-2.25%-1.36%-41.03%-68.49%-97.41%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-6.08%-2.52%-1.40%+33.74%-44.18%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%0.00%+26.67%-60.00%-96.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$2.17
-2.3%		$4.21
$2.05
▼
$179.19
$1.28M-0.0744,881 shs45,256 shs
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.40
-6.1%		$0.47
$0.15
▼
$0.97
$1.32M-0.236,551 shs2,097 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.19
$0.17
$0.00
▼
$6.53
$340K0.51,216 shs403 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-2.25%-1.36%-41.03%-68.49%-97.41%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-6.08%-2.52%-1.40%+33.74%-44.18%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%0.00%+26.67%-60.00%-96.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
1.50
ReduceN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest LYRA, ATXI, ASLN, and ARTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A($17.03) per shareN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$400K0.84N/AN/A($6.04) per share-0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$12.88M-$151.22N/AN/AN/AN/A-518.27%-194.29%11/17/2026 (Estimated)
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.850.02N/AN/AN/A-471.57%-296.50%11/13/2026 (Estimated)
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$28.92M-$19.15N/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)

Latest LYRA, ATXI, ASLN, and ARTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2026Q3 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$7.02N/AN/AN/AN/AN/A
11/17/2026N/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$1.63N/AN/AN/A$0.10 millionN/A
11/13/2026N/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$56.25N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$6.48-$0.89+$5.59-$8.01N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
3.00
3.00
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
95.62%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20%
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
8.60%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
3.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
7550,000530,000Not Optionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.30 million2.02 millionNot Optionable
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
501.77 million1.72 millionNo Data

Recent News About These Companies

Lyra Therapeutics stock centers on its nasal drug pipeline
October 15, 2026  |  ad-hoc-news.deA
Lyra Therapeutics stock falls 3.50 percent in OTC trading
October 5, 2026  |  ad-hoc-news.deA
Lyra Therapeutics stock trades OTC at USD 0.15 after delisting
October 4, 2026  |  ad-hoc-news.deA
Head to Head Contrast: Lyra Therapeutics (OTCMKTS:LYRA) versus Cronos Group (NASDAQ:CRON)
September 24, 2026  |  defenseworld.netD
Lyra Therapeutics stock holds its Nasdaq listing as results await
September 23, 2026  |  ad-hoc-news.deA
Lyra Therapeutics stock holds steady as investors eye recent trial and cash runway
September 20, 2026  |  ad-hoc-news.deA
Lyra Therapeutics Inc.
August 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/lyra/financials/cash-flow
Lyra Therapeutics Ends Major Office Sublease Agreement
April 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-ends-major-office-sublease-agreement?utm_source=marketbeat.com&utm_medium=referral
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276116/0/en/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec.html
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases
April 14, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/04/13/lyra-terminates-leases.html
Lyra Therapeutics Walks Away From Watertown, Waltham Lab Space
April 14, 2026  |  hoodline.comH
Treating allergic fungal rhinosinusitis in children
April 8, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/treating-allergic-fungal-rhinosinusitis-in-children/ar-AA20r233
Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting
March 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-withdraws-nasdaq-appeal-faces-imminent-delisting?utm_source=marketbeat.com&utm_medium=referral
Lyra Therapeutics (LYRA) price target decreased by 30.43% to 16.32
February 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/lyra-therapeutics-lyra-price-target-decreased-by-3043-to-1632/ar-AA1VETSX
Lyra Therapeutics suspends further development of LYR-210
January 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/lyra-therapeutics-suspends-further-development-122631308.html
Lyra ditches sole rhinosinusitis asset, lays off all employees
January 13, 2026  |  fiercebiotech.comF
Watertown biotech suspends drug development and eliminates workforce as cash dwindles
January 12, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/01/12/lyra-layoffs-halt-development.html
Lyra Therapeutics Suspends Development of Lead Product Candidate
January 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/lyra-therapeutics-suspends-development-of-lead-product-candidate-c11f109d
Lyra Therapeutics Provides Corporate Update
January 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/12/3216724/0/en/lyra-therapeutics-provides-corporate-update.html
William Blair Reaffirms Their Hold Rating on Lyra Therapeutics (LYRA)
November 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LYRA/pressreleases/35290143/william-blair-reaffirms-their-hold-rating-on-lyra-therapeutics-lyra/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$2.17 -0.05 (-2.25%)
Closing price 11/2/2026 03:59 PM Eastern
Extended Trading
$2.15 -0.02 (-1.11%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 10/30/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.40 -0.03 (-6.08%)
As of 11/2/2026 03:18 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Lyra Therapeutics stock logo

Lyra Therapeutics OTCMKTS:LYRA

$0.19 0.00 (0.00%)
As of 11/2/2026 09:48 AM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas